O-glycoside Patents (Class 514/25)
  • Patent number: 11912670
    Abstract: A ethyl 4-(5-(3-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)butanoate compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: October 25, 2023
    Date of Patent: February 27, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11903946
    Abstract: The present invention is related to novel compositions comprising at least one active ingredient of the family of the triazines combined with another active ingredient and specific compounds that allow the reduction of foam formation. More particularly, the invention relates to compositions in the form of aqueous suspensions comprising a triazine, an iron complex, and one or more surfactant(s) having a particular HLB.
    Type: Grant
    Filed: October 6, 2021
    Date of Patent: February 20, 2024
    Assignee: CEVA SANTE ANIMALE
    Inventors: Anne-Claire Le Meur, Florence Guimberteau
  • Patent number: 11883453
    Abstract: This invention refers to a formulation comprising at least one medicinal plant, part or extract of it, one or more extracting agents and one or more pharmaceutically or cosmetically acceptable excipients that generate a plant extract (plant derivative) with a high bioactive content for regeneration of the skin, dermal mucous membrane and related parts, used as an active pharmaceutical ingredient to treat wounds of any kind or as a cosmetic ingredient for protection, maintenance and natural balance of the skin, dermal mucous membrane and related parts. The use of this formulation generates pharmaceutical products of high efficacy, of topic used, which provide treatments of low cost, reduced time and of less complexity of the procedures by the healthcare professionals, intended to the treatment of chronic and acute lesions of the skin, dermal mucous membrane and related parts.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: January 30, 2024
    Inventor: Alessandro Afornali
  • Patent number: 11884672
    Abstract: The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I): tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: January 30, 2024
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Upul Keerthi Bandarage, Cavan McKeon Bligh, Diane Boucher, Michael John Boyd, Michael Aaron Brodney, Michael Philip Clark, Veronique Damagnez, Lev Tyler Dewey Fanning, Robert Francis Fimognari, Gabrielle Simone Fleming, Kevin James Gagnon, Pedro Manuel Garcia Barrantes, Robert Daniel Giacometti, Simon Giroux, Ronald Lee Grey, Jr., Samantha Guido, Amy Beth Hall, Sarah Carol Hood, Dennis James Hurley, Mac Arthur Johnson, Jr., Peter Jones, Sarathy Kesavan, Mei-Hsiu Lai, Siying Liu, Adam Looker, Brad Maxwell, John Patrick Maxwell, Ales Medek, Philippe Marcel Nuhant, Kirk Alan Overhoff, Setu Roday, Stefanie Roeper, Steven M. Ronkin, Rupa Sawant, Yi Shi, Muna Shrestha, Marisa Sposato, Kathy Stavropoulos, Rebecca Jane Swett, Timothy Lewis Tapley, Qing Tang, Stephen Thomson, Jinwang Xu, Mariam Zaky, Kevin Michael Cottrell
  • Patent number: 11872263
    Abstract: The present invention relates to novel fragments of AIMP1 protein and a composition for improving alopecia and promoting hair growth comprising the same, more specifically it relates to a polypeptide consisting of 4 to 21 consecutive amino acids from the amino acid sequence of SEQ ID NO: 1, wherein the polypeptide comprises the 28th to 31st amino acid residue (KEKA) of amino acid sequence of SEQ ID NO: 1, or a polypeptide consisting of an amino acid sequence having 70% or more sequence homology with the polypeptide; a polynucleotide encoding the polypeptide; a pharmaceutical, cosmetic and food composition for improving alopecia and promoting hair growth comprising the polypeptide.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: January 16, 2024
    Assignee: CUREBIO THERAPEUTICS
    Inventors: Sunghoon Kim, Min Chul Park, Younha Kim
  • Patent number: 11813272
    Abstract: Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: November 14, 2023
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Steven John Taylor, John Robert Proudfoot, Mi-Jeong Kim, Kathleen Nudel, Timothy F. Briggs, Afrand Kamali Sarvestani, Leonard Buckbinder, Bernard Lanter, Ferdinand Edward Massari, Koji Yasuda, Spencer Cory Peck, Cheri Snedeker, Diana Le, Jessica Alexander, Anna Liang, Dinara Gunasekera, David Arthur Berry, John Patrick Casey, Jr.
  • Patent number: 11813233
    Abstract: A method of attenuating, treating or preventing cognitive aging in an individual who does not have dementia includes administering to the individual a therapeutically effective amount of a composition containing an omega-3 fatty acid and choline. The method can achieve a benefit that is one or more of decreasing brain atrophy, increasing or maintaining number of synapses, increasing amyloid-? phagocytosis, or decreasing or maintaining neuroinflammation in the non-demented individual. The method can prevent dementia in an individual at risk thereof, for example an elderly human. The composition can be administered to the individual in a daily dose that provides 5.5 mg/day to 5,500 mg/day of the choline, for example 85 mg/day to 3,500 mg/day of the choline.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: November 14, 2023
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Claus Rieker, Julie Hudry-Labbe, Jeroen Antonius Johannes Schmitt, Corina Boschat, Yvonne Beata Silber
  • Patent number: 11801277
    Abstract: The invention discloses synergistic herbal composition comprising combination of first ingredient selected from extracts, fractions, phytochemicals and mixtures thereof derived from Theobroma cacao and a second ingredient selected from extracts, fractions, phytochemical and mixtures thereof derived from Citrus aurantifolia for obtaining at least one health benefit selected from preventing, controlling or treating obesity and/or overweight; improving lean body mass, improving the browning of White Adipose Tissue/improving formation of brown adipose tissue, increasing basal metabolic rate/resting energy expenditure, increasing thermogenesis, improving thyroid function, maintaining healthy body weight, increasing satiety/, supporting weight loss, improving fat loss and maintaining a slim body.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: October 31, 2023
    Assignee: Laila Nutraceuticals
    Inventors: Ganga Raju Gokaraju, Venkata Kanaka Ranga Raju Gokaraju, Rama Raju Gokaraju, Trimurtulu Golakoti, Kiran Bhupathiraju, Venkateswarlu Somepalli, Venkata Krishna Raju Alluri, Krishanu Senguptha
  • Patent number: 11786586
    Abstract: The present invention provides methods and compositions related to multivalent carbohydrate antigen structures comprising cancer or infection associated ganglioside carbohydrate antigens. Said carbohydrate structures may be used to induce immunity against said carbohydrate antigens. In some embodiments, carbohydrate structures may be administered to a subject thereby inducing immunity in the subject, for example, the administration of a vaccine comprising said carbohydrate structure. Also provided are methods to induce an immune response in a subject in need thereof by administering said carbohydrate structure. Further provided are methods of producing an antibody or TCR that bind said carbohydrate antigens.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: October 17, 2023
    Assignee: AOA Dx
    Inventor: Horacio Uri Saragovi
  • Patent number: 11790440
    Abstract: Systems and methods for providing a search-directed user interface for online banking applications. An example method may comprise: receiving, via a graphical user interface (GUI) session associated with an authenticated user, a search argument comprising a character string; executing, by a processing device, a search query by matching the character string to account data of one or more accounts that the authenticated user is authorized to access, the account data comprising a plurality of data items representing at least one of: financial product types, financial product identifiers, financial transaction types, financial transaction descriptions, financial transaction amounts, portfolio types, accounts, and aggregated financial indicators; and causing a data set produced by executing the search query to be visually represented via the GUI session.
    Type: Grant
    Filed: September 13, 2022
    Date of Patent: October 17, 2023
    Assignee: Teachers Insurance and Annuity Association of America
    Inventors: Scott M. Blandford, Robert A. Lindenberg, Laura Shragowitz, Charles Reitzel, Albert F. Cole, Jr.
  • Patent number: 11691995
    Abstract: The presently disclosed subject matter relates to nitric oxide-releasing particles for delivering nitric oxide, and their use in biomedical and pharmaceutical applications.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: July 4, 2023
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Mark H. Schoenfisch, Jae Ho Shin, Nathan Stasko
  • Patent number: 11691035
    Abstract: Provided is a composition for the treatment of keratin fibers, for example human keratin fibers such as the hair, comprising, in a cosmetically acceptable medium, at least one cationic polymer; at least one fatty amide; at least one anti-oxygen agent; and at least one oxidizing agent; wherein the pH of the composition ranges from 1.5 to 4.5. Also provided is a composition for the treatment of keratin fibers, comprising, in a cosmetically acceptable medium, at least one cationic polymer; at least one fatty amide; at least one anti-oxygen agent; and at least one oxidizing agent; wherein the pH of the composition is alkaline. Also provided is a method for treating keratin fibers, comprising applying, to the keratin fibers, at least one oxidizing composition described herein.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: July 4, 2023
    Assignee: L'OREAL
    Inventors: Damarys Braida-Valerio, Laurent Nodari, Jean Cotteret
  • Patent number: 11627753
    Abstract: Various embodiments of the present technology provide a sweetener composition comprising stevia glycosides that may be stably soluble in an aqueous solution, and methods for their manufacture. In various embodiments, the sweetener composition may comprise at least one stevia glycoside and a natural emulsifier. The natural emulsifier of the sweetener composition may enhance the aqueous solubility of the stevia glycoside to increase the concentration of dissolved stevia glycoside relative to its inherent aqueous solubility. The sweetener composition may be stably soluble upon formulation into any edible sweetened substances.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: April 18, 2023
    Assignee: James and Carol May Family, LLLP
    Inventors: Venkata Sai Prakash Chaturvedula, Michael Perry May, James A. May, Julian E. Zamora
  • Patent number: 11590236
    Abstract: Disclosed are methods and compositions for repolarizing a tumor associated macrophage (TAM) from M2 to M1 comprising administering to a subject in need thereof an effective dose of a compound comprising a dextran backbone and one or more CD206 targeting moieties conjugated thereto. In certain aspects, the compound further comprises a therapeutic agent selected from: paclitaxel, gemcitabine, lapatinib, and doxorubicin. In further aspect, the therapeutic agent comprises a chelator and at least one metal ion. In certain implementations, the at least one metal ion comprises at least one Cu(II) ions.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: February 28, 2023
    Assignee: Navidea Biopharmaceuticals, Inc.
    Inventor: David A. Ralph
  • Patent number: 11566040
    Abstract: Disclosed is synthesis of an O-Antigen oligosaccharide compound of Helicobacter pylori serotype O2, belonging to the field of organic synthesis. The disclosure obtains O-antigen disaccharide to tetracosasaccharide of Helicobacter pylori serotype O2 by chemical synthesis. A chemical synthesis method which is quite conducive to production of a glucose-?-lglucosidic bond is developed in the disclosure by a protectant strategy, temperature effect, solvent effect, and additive effect. The method is applied in synthesis of an O-antigen oligosaccharide compound of Helicobacter pylori serotype O2 assembled with an amino linking arm. A saccharide conjugate can be prepared from the synthesized O-antigen oligosaccharide compound of Helicobacter pylori serotype O2 assembled with an amino linking arm together with a carrier protein for immunology researches, playing an important role in preventing and treating Helicobacter pylori.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: January 31, 2023
    Assignee: Jiangnan University
    Inventors: Jian Yin, Jing Hu, Zhonghua Liu, Chunjun Qin
  • Patent number: 11559568
    Abstract: Provided herein, in some aspects, are delivery vehicles comprising a glycosphingolipid and an agent to be delivered attached to the glycosphingolipid. In some embodiments, the glycosphingolipid comprises an oligosaccharide and a short chain (e.g., C0-C3) ceramide. In some embodiments, the agent to be delivered is a therapeutic agent. The glycosphingolipid is able to deliver the agent to a cell or to a cellular compartment, as well as across the musical barrier. In some embodiments, agents delivered using the glycosphingolipid described herein exhibit longer half-life, compared to agents delivered alone. Methods of delivering a therapeutic agent to a subject for treating a disease using the glycosphingolipid delivery vehicle are also provided.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: January 24, 2023
    Assignee: Children's Medical Center Corporation
    Inventors: Wayne I. Lencer, Daniel J F Chinnapen
  • Patent number: 11547652
    Abstract: This invention relates to a cosmetic combination product comprising a first cosmetic composition comprising glucosamine or one of the salts thereof, a second cosmetic composition comprising hyaluronic acid, and possibly a third cosmetic composition comprising collagen, a cosmetic composition comprising glucosamine or one of the salts thereof, hyaluronic acid, and possibly collagen, the uses thereof, in particular for inducing the synthesis of hyaluronic acid and as such combat aging of the skin affecting the keratinocytes and/or the fibroblasts and the dermis, as well as a cosmetic method that implements these combination products and compositions.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: January 10, 2023
    Assignee: NUTRICOS TECHNOLOGIES
    Inventors: Yann Mahe, Carole Bru
  • Patent number: 11535814
    Abstract: The invention relates to surfactants of general formula (I) in which R represents a linear or branched alkyl, alkenyl, alkylaryl or alkenylaryl group having 5-25 C atoms and X+ represents a charge-balancing cation. The surfactants can be incorporated into detergents or cleaning agents, have excellent technological application properties and can be produced based on renewable raw materials.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: December 27, 2022
    Assignee: Henkel AG & Co. KGaA
    Inventors: Christian Kropf, Anna Klemmer, Danuta Bedrunka, Regina Palkovits, Peter Hausoul, Lukas Kipshagen
  • Patent number: 11523630
    Abstract: Provided are food compositions configured to promote neurodevelopment in developing subjects. Food compositions of the present disclosure may make available to a subject those nutrients that are required by or otherwise positively influence developing brain regions, and the neurons thereof, during specific windows of neurodevelopment. Also provided are kits and systems that relate to the subject food compositions as well as methods, such as methods of formulating the described food compositions.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: December 13, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventor: Teresa Purzner
  • Patent number: 11517600
    Abstract: A method for treating breast cancer and/or treating breast cancer metastasis in a subject in need of such treatment including administering to said subject an effective amount of Crassocephalum rabens extract and optionally a pharmaceutically acceptable carrier or excipient.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: December 6, 2022
    Assignee: ACADEMIA SINICA
    Inventors: Lie-Fen Shyur, Maria Karmella Apaya, Meng-Ting Chang
  • Patent number: 11510878
    Abstract: The present invention relates to an extended release multiparticulate composition comprising a plurality of discrete units, each discrete unit comprising ranolazine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The said multiparticulate composition is sprinkled onto soft foods or liquids for oral administration. Further, the multiparticulate composition is bioequivalent to the marketed extended release tablet. It further relates to a process of preparation of said multiparticulate composition and method of treatment of patients suffering from angina by administering said composition.
    Type: Grant
    Filed: December 21, 2020
    Date of Patent: November 29, 2022
    Assignee: Sun Pharmaceutical Industries Limited
    Inventors: Harinder Singh, Shavej Ahmad, Romi B. Singh
  • Patent number: 11497759
    Abstract: A therapeutic compound having intrinsic anti-mitochondrial properties may be chemically modified to target the compound to mitochondria, and the resulting “repurposcins” may have enhanced anti-cancer properties, among other advantageous properties. For example, a repurposcin may be used to treat and/or prevent tumor recurrence, metastasis, drug resistance, and/or radiotherapy resistance. Described herein are repurposcin compounds and pharmaceutical compositions that have been developed according to the present approach. Also described are methods for identifying and developing repurposcins, methods of using repurposcins to target cancer stem cells, and compositions for treating cancer containing one or more repurposcins as the active ingredient.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: November 15, 2022
    Assignee: LUNELLA BIOTECH, INC.
    Inventors: Michael P. Lisanti, Federica Sotgia
  • Patent number: 11471430
    Abstract: Provided herein is a group of sphingosine analogs, useful in the treatment of bacterial infections in mucosal surfaces such as lungs, caused by pathogenic bacteria which are typical to disorders and diseases such as CF and COPD.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: October 18, 2022
    Assignees: Yeda Research and Development Co. Ltd., University of Duisburg-Essen
    Inventors: Anthony H. Futerman, Tammar Joseph, Walter A. Shaw, Stephen W. Burgess, Shengrong Li
  • Patent number: 11440931
    Abstract: Provided are a series of crocins compounds and related pharmacological applications thereof in prevention and treatment of Alzheimer's disease. The series of crocins compounds are obtained by taking the Chinese herb, namely Gardenia jasminoides Ellis, as a raw material and separating same by means of various methods. The compounds playing a role in preventing oxidative injury caused by hydrogen peroxide (H2O2) and excitatory amino acid injury caused by L-glutamic acid are screened out by in-vitro cell experiments. The results show that the crocins compounds have good effect in preventing cell injury caused by H2O2 and L-glutamic acid. The compounds have good effect in preventing and treating Alzheimer's disease due to the fact that significant rise of oxidative stress and excitatory amino acid is a key factor for nerve injury in Alzheimer's disease, and have broad development and application prospect.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: September 13, 2022
    Assignee: Jinan University
    Inventors: Xinsheng Yao, Yang Yu, Dan Zhang, Yang Ni, Xiuqi Bao, Lin Li, Caixía Zang, Hao Gao, Yuanpeng Zheng
  • Patent number: 11370848
    Abstract: A glycosaminoglycan derivative endowed with heparanase inhibitory activity and antitumor activity, bearing carboxylate groups in positions 2 and 3 of at least part of the glycosaminoglycan residues, and to the process for preparing the same. The glycosaminoglycan derivatives of the present invention are generated starting from natural or synthetic glycosaminoglycans, preferably heparin or low molecular weight heparin, optionally 2-O- and 2-N-desulfated by two steps of oxidation. By the first oxidation, adjacent dials and optionally adjacent OH/NH2 of the glycosaminoglycan residues are converted to aldehydes and by the second oxidation said dialdehydes are converted to carboxylate groups. The first oxidation preferably leads to the cleavage of C2-C3 linkage of the ring of oxidable residues. The invention relates to a process for the preparation of said glycosaminoglycan derivatives and to their use as active ingredients of medicaments.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: June 28, 2022
    Assignee: Novahealth Biosystems, LLC
    Inventors: Giangiacomo Torri, Annamaria Naggi
  • Patent number: 11357746
    Abstract: The present invention relates to use of a composition comprising D-glyceric acid (DGA), DL-glyceric acid, L-glyceric acid, or hydroxypyruvatic acid and/or their salts or esters. Further, the invention relates to the use of said composition for enhancing direct and indirect mitochondrial metabolism, e.g. the ATP producing electron transport system (ETS), citric acid cycle or tricarboxylic acid cycle, (TCA), and beta oxidation, and also enhancing the shuttling of reducing equivalents from mitochondrial matrix into the cytosol and protein synthesis in the endoplasmic reticulum. Directly related to the above the use of DGA relates also to reducing the formation of reactive oxygen species (ROS). Alleviating, preventing and even healing effects towards extremely wide range of non-communicable diseases materializes.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: June 14, 2022
    Assignee: REPLICON HEALTH OY
    Inventors: Petteri Hirvonen, Peter Eriksson, Risto Kaksonen
  • Patent number: 11337428
    Abstract: An aqueous extract of Larrea tridentata useful in the control of phytopathogens that attack commercial crops, functionalized to increase the ratio of quinones of nordihydroguaiaretic acid.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: May 24, 2022
    Inventors: Juan Genaro Osuna Sanchez, Yolanda Sanchez Salazar, Yolanda Osuna Sanchez
  • Patent number: 11332548
    Abstract: A glycosaminoglycan derivative endowed with heparanase inhibitory activity and antitumor activity, bearing carboxylate groups in positions 2 and 3 of at least part of the glycosaminoglycan residues, and to the process for preparing the same. The glycosaminoglycan derivatives of the present invention are generated starting from natural or synthetic glycosaminoglycans, preferably heparin or low molecular weight heparin, optionally 2-O- and 2-N-desulfated by two steps of oxidation. By the first oxidation, adjacent dials and optionally adjacent OH/NH2 of the glycosaminoglycan residues are converted to aldehydes and by the second oxidation said dialdehydes are converted to carboxylate groups. The first oxidation preferably leads to the cleavage of C2-C3 linkage of the ring of oxidable residues. The invention relates to a process for the preparation of said glycosaminoglycan derivatives and to their use as active ingredients of medicaments.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: May 17, 2022
    Assignee: Novahealth Biosystems, LLC
    Inventors: Giangiacomo Torri, Annamaria Naggi
  • Patent number: 11311601
    Abstract: The present invention relates to novel fragments of AIMP1 protein and a composition for improving alopecia and promoting hair growth comprising the same, more specifically it relates to a polypeptide consisting of 4 to 21 consecutive amino acids from the amino acid sequence of SEQ ID NO: 1, wherein the polypeptide comprises the 28th to 31st amino acid residue (KEKA) of amino acid sequence of SEQ ID NO: 1, or a polypeptide consisting of an amino acid sequence having 70% or more sequence homology with the polypeptide; a polynucleotide encoding the polypeptide; a pharmaceutical, cosmetic and food composition for improving alopecia and promoting hair growth comprising the polypeptide.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: April 26, 2022
    Assignee: CUREBIO THERAPEUTICS
    Inventors: Sunghoon Kim, Min Chul Park, Younha Kim
  • Patent number: 11306339
    Abstract: A method for the production of a rhamnolipid. The method includes culturing in a fermentation medium an organism capable of producing a rhamnolipid to form a fermentation broth comprising at least one rhamnolipid and having a pH>5; extracting at least one lipophilic impurity from said fermentation broth; acidulating said fermentation broth to form an aqueous medium of pH<5 comprising the at least one rhamnolipid; extracting the at least one rhamnolipid from said acidulated fermentation broth; and separating the at least one rhamnolipid to obtain a purified rhamnolipid.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: April 19, 2022
    Assignee: SUPERBREWED FOOD, INC.
    Inventors: Aharon M. Eyal, Bryan P. Tracy, Christopher Joseph McWilliams
  • Patent number: 11306115
    Abstract: Novel pseudo-disaccharide and pseudo-trisaccharide aminoglycosides, represented by Formulae I or Ia, as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic diseases and disorders, such as diseases and disorders associated with stop codon mutations.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: April 19, 2022
    Assignee: ELOXX PHARMACEUTICALS LTD.
    Inventor: Timor Baasov
  • Patent number: 11278483
    Abstract: A cosmetic ingredient comprising crenatoside and acteoside when applied to the skin is useful to provide cosmetic and perfumery benefits.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: March 22, 2022
    Assignee: GIVAUDAN SA
    Inventors: Fabrice Lefevre, Daniel Auriol, Cyrille Jarrin, Patrick Robe, Romain Reynaud
  • Patent number: 11191814
    Abstract: A food supplement is disclosed that comprises an extracellular matrix composition of hydrolyzed collagen, hyaluronic acid and glucosamine, ascorbic acid and, optionally, a cannabinoid composition. The food supplement can be given to pet animals for the relief of or prophylaxis of degenerative joint diseases, such as arthritis.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: December 7, 2021
    Assignee: PAW POWER, INC.
    Inventor: Anja Skodda
  • Patent number: 11191729
    Abstract: The use of a granular material which is for orally fast disintegrating tablets and comprises starch and tannic acid allows provision of tablets that can be produced by a simple process with general-purpose production equipment, disintegrate fast and absorbs water in the mouth, and have a proper level of shape retainability for practical use. The present invention also provides a method for producing an orally fast disintegrating tablet, the method comprising compression molding of a granular material for orally fast disintegrating tablets comprising starch and tannic acid, or a mixture of the granular material for orally fast disintegrating tablets and other ingredients (an additive, an active ingredient, and/or the like).
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: December 7, 2021
    Assignee: Teika Pharmaceutical Co., Ltd.
    Inventors: Takao Shimatani, Yutaka Hasegawa, Hiroko Ito, Takahiro Kawagishi, Naohisa Wada, Atsushi Yamada
  • Patent number: 11186812
    Abstract: An optofluidic photoreactor including an optical waveguide having an input, characterized by an evanescent optical field confined along an outer surface of the optical waveguide produced by radiation propagating in the optical waveguide, means for inputting light to the input of the optical waveguide, and a photoactive material disposed substantially only within the evanescent field. A method for optically activating a photoactive material in an optofluidic photoreactor to convert carbon dioxide and water into other molecules that may be useful as a fuel or a chemical feedstock.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: November 30, 2021
    Assignee: CORNELL UNIVERSITY
    Inventors: David Erickson, Perry M. Schein
  • Patent number: 11179408
    Abstract: The present invention relates to the use of cyanoglucoside according to formula (I) and formulations thereof in the prevention and/or treatment of diabetes and/or metabolic syndrome; wherein R1, R2 and R3 are independently selected from an optionally substituted mono- or di-saccharide, —O—R4, —O—C(O)—R4 and halogen, such as Cl, F or Br, wherein R4 is selected from H, alkyl, such as methyl, as well as tautomers, geometrical isomers, optically active forms, pharmaceutically acceptable salts and pharmaceutically active derivative thereof.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: November 23, 2021
    Assignees: UNIVERSITÉ DE GENÈVE, UNIVERSIDADE ESTADUAL PAULISTA JÚLIO DE MESQUITA FILHO
    Inventors: Luiz Leonardo Saldanha, Anne Ligia Dokkedal Bosqueiro, Jose Roberto Bosqueiro, Nathalia Aparecida De Paula Camaforte Henriques, Priscilla Maria Ponce Vareda, Wagner Vilegas, Emerson Ferreira Queiroz, Laurence Marcourt, Jean-Luc Wolfender
  • Patent number: 11173177
    Abstract: The present disclosure relates to use of heparin analogues as inhibitors of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) for the treatment of lipoprotein metabolism disorders.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: November 16, 2021
    Assignee: Aarhus Universitet
    Inventors: Camilla Gustafsen, Peder Sondergaard Madsen, Simon Glerup Pedersen
  • Patent number: 11166973
    Abstract: This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating viral infections, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: November 9, 2021
    Assignee: Emory University
    Inventors: Dennis C. Liotta, George R. Painter, Gregory R. Bluemling, Abel de la Rosa
  • Patent number: 11161868
    Abstract: The present invention provides N-acetyl derivatives of sialic acids, including N-acetyl derivatives of Neu5Ac and Neu5Gc. Methods for preparing related precursors and a variety of sialosides are also disclosed.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: November 2, 2021
    Assignee: The Regents of the University of California
    Inventors: Xi Chen, An Xiao, Anoopjit Kooner, Abhishek Santra, Ajit Varki, Hai Yu, Lee-Ping Wang, Wanqing Li
  • Patent number: 11160782
    Abstract: A nobiletin composition having high water solubility and a method for easily producing the same are provided. A method for producing a solid dispersion comprising nobiletin, comprising the step of mixing nobiletin or a nobiletin-containing product with a water-soluble hesperidin derivative, and then melting the mixture by heating; and the step of solidifying the melted product by cooling. A nobiletin-containing composition produced by the method.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: November 2, 2021
    Assignee: KAO CORPORATION
    Inventors: Masazumi Iwashita, Masahiro Umehara, Shintaro Onishi, Masaki Yamamoto, Keisuke Yamagami, Takaaki Ishigami
  • Patent number: 11142492
    Abstract: Methods of isolating phenols from phenol-containing media. The methods include combining a phospholipid-containing composition with the phenol-containing medium to generate a combined medium, incubating the combined medium to precipitate phenols in the combined medium and thereby form a phenol precipitate phase and a phenol-depleted phase, and separating the phenol precipitate phase and the phenol-depleted phase. The methods can further include extracting phenols from the separated phenol precipitate phase. The extracting can include mixing the separated phenol precipitate phase with an extraction solvent to solubilize in the extraction solvent at least a portion of the phenols originally present in the phenol precipitate phase.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: October 12, 2021
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Bradley Bolling, Yuwei Wu, Danielle Voss, Matthew Dorris
  • Patent number: 11141379
    Abstract: The present invention encompasses prodrug compositions, nanoparticles comprising one or more prodrugs, and methods of use thereof.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: October 12, 2021
    Assignee: Washington University
    Inventors: Gregory M. Lanza, Dipanjan Pan
  • Patent number: 11141371
    Abstract: New extracts of Nannochloropsis sp. and related species of Nannochloropsis are suggested, obtainable by treating said microalgae with a solvent selected from the group consisting of C1-C1 aliphatic alcohols, ethyl acetate, water or their mixtures, removing the dissolved extracts from the residues and recovering the pure extracts from the solvent. The extracts show excellent properties particularly in modulating the metabolism of human skin and hair follicles.
    Type: Grant
    Filed: August 8, 2015
    Date of Patent: October 12, 2021
    Assignee: Symrise AG
    Inventors: Lorenzo Zanella, Paolo Pertile
  • Patent number: 11096935
    Abstract: The present invention provides methods of use of hexokinase 2 (HK2)/mitochondria-detaching compounds, including jasmonate derivatives and piperazine derivatives and pharmaceutical compositions including such compounds for inducing immune responses in a subject, including potentiating the immune response to hyperproliferative disorders such as cancer and potentiating the immune response to infectious diseases.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: August 24, 2021
    Assignee: VIDAC PHARMA LTD
    Inventors: Vered Behar, Oren Menahem Becker, Reut Yosef Hamo, Eyal Dor-On
  • Patent number: 11090349
    Abstract: An extract from leaves of mulberry is disclosed. The extract has an IC50 value sufficient to inhibit ?-glucosidase I. The extract may comprise 5-40% (w/w) total imino sugars and 20-70% (w/w) total amino acids. The extract may reduce the production of melanin for the treatment of such ailments or diseases caused by pigmentation as freckle, chloasma, striae gravidarum, sensile plaque and melanoma. The extract may also control blood glucose level.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: August 17, 2021
    Inventors: Chen Xie, Yingshu Zou
  • Patent number: 11071718
    Abstract: Provided are methods of treating a neurological or psychiatric disorder in a subject in need thereof, comprising: administering to the subject a therapeutically effective amount of ketamine or a pharmaceutically acceptable salt thereof in combination with an amount of one or more compounds effective to increase the level of nicotinamide adenine dinucleotide (NAD+) in the subject.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: July 27, 2021
    Assignee: BNIW Ventures LLC.
    Inventors: Guriqbal S. Nandra, Irvin M. Wiesman
  • Patent number: 11058698
    Abstract: Disclosed herein are acylated active agents and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: July 13, 2021
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Steven John Taylor, Mi-Jeong Kim, Kathleen Nudel, Timothy F. Briggs, Koji Yasuda, Leonard Buckbinder, Bernard Lanter, Spencer Cory Peck, Cheri Snedeker, Angela She, Jessica Alexander, Anna Liang, Jenny Liu, Dinara Gunasekera, David Arthur Berry, John Patrick Casey, Jr., Amir H. Moarefi
  • Patent number: 11000535
    Abstract: A composition for inhibiting a liver tumor in an organism is disclosed. The composition includes an activator being 1,2,3,4,6-penta-O-galloyl-Beta-D-glucopyranoside (PGG), wherein PGG is extracted from at least one of Paeonia lactiflora Pall. and Galla Chinesis.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: May 11, 2021
    Assignee: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Yi-Ming Chen, Chia-Hung Yen, Chung-Kuang Lu
  • Patent number: 10988731
    Abstract: A method of creating a protein rich conditioned medium. The method includes culturing mesenchymal stem cells in a container utilizing a first growth medium, allowing a time period for proliferation of the mesenchymal stem cells until a desired level of confluence is achieved in the container, discarding a supernatant from the container, adding a second medium to the container, incubating the mesenchymal stem cells, and collecting the conditioned medium. The method produces significantly higher quantities of byproducts secreted by the mesenchymal stem cells. Byproducts are usable for wound healing, disease treatment, cosmetic, or other beneficial effects when applied or otherwise delivered to a patient.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: April 27, 2021
    Assignee: HOPE BIOSCIENCES, LLC
    Inventors: Hyeonggeun Park, Fred Haisam Khoury
  • Patent number: 10966918
    Abstract: Disclosed are methods of treating skin with topical skin compositions comprising at least one plant extract.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: April 6, 2021
    Assignee: Mary Kay Inc.
    Inventors: Tiffany Florence, David Gan, Michelle Hines